Related Experiment Video

Updated: Jan 15, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.5K

Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling

Tareq Al Baghdadi1, Michael Rothe2, Pam K Mangat2

  • 1Michigan Cancer Research Consortium, IHA Hematology Oncology, Ypsilanti, MI.

JCO Precision Oncology
|October 16, 2025
PubMed
Abstract

Insights

Olaparib demonstrated significant antitumor activity in patients with advanced solid tumors harboring BRCA1/2 mutations. This targeted therapy showed promising disease control rates across multiple cancer types, warranting further investigation.

Area of Science:

  • Oncology
  • Genomics
  • Clinical Trials

Background:

  • The Targeted Agent and Profiling Utilization Registry Study (TAPUR) is a phase II basket trial.
  • Investigating targeted agents in advanced cancers with genomic alterations.

Purpose of the Study:

  • Evaluate the antitumor activity of olaparib in patients with advanced solid tumors and BRCA1/2 mutations.
  • Assess olaparib's efficacy across five distinct cancer cohorts: breast, biliary tract, lung, uterine, and other solid tumors.

Main Methods:

  • Phase II basket trial design with five patient cohorts.
  • Primary endpoint: disease control (DC) rate defined as complete response, partial response, or stable disease (SD) for at least 16 weeks.
  • Utilized Simon two-stage design for histology-specific cohorts and a one-sided exact binomial test for smaller cohorts.

Main Results:

  • Enrolled 119 patients with BRCA1/2-altered advanced solid tumors.
  • Achieved significant disease control rates across all cohorts, exceeding the null hypothesis of 15% DC.
  • Reported DC rates ranged from 41% to 69%, with notable efficacy in breast and biliary tract cancers.

Conclusions:

  • Olaparib demonstrated a signal of clinical activity in patients with various advanced BRCA1/2-altered solid tumors.
  • The study met its prespecified criteria for declaring efficacy.
  • Results support olaparib as a potential targeted therapy for BRCA1/2-mutated solid malignancies.

More Related Videos

Evaluating In Vitro DNA Damage Using Comet Assay10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

39.4K
gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

12.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.4K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K